Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 167 results for ckd

  1. Frequency of review: What is the most clinical and cost-effective frequency of review for children and young people with CKD?

    people with CKD? Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...

    Research recommendation
    Published
    30 September 2021

  2. Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring frequency for albumin:creatinine ratio?

    Question Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring frequency for...

    Research recommendation
    Published
    30 September 2021

  3. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  4. Creatinine-based estimate of eGFR – existing calculations: In adults, children and young people from black, Asian and other minority ethnic groups with chronic kidney disease (CKD) living in the UK, which existing eGFR calculations are the most accurate?

    people from black, Asian and other minority ethnic groups with chronic kidney disease (CKD) living in the UK, which...

    Research recommendation
    Published
    30 September 2021

  5. Managing anaemia – optimal Hb levels for children and young people: What is the efficacy and safety of different aspirational haemoglobin (Hb) targets for children and young people with CKD undergoing treatment for anaemia?

    aspirational haemoglobin (Hb) targets for children and young people with CKD undergoing treatment for anaemia? Any explanatory notes(if...

    Research recommendation
    Published
    30 September 2021

  6. Risk assessment, referral criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people?

    criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people? Any explanatory...

    Research recommendation
    Published
    30 September 2021

  7. Managing anaemia: What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with CKD?

    people with CKD? Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...

    Research recommendation
    Published
    30 September 2021

  8. Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of renin–angiotensin–aldosterone system (RAAS) antagonists? [2014]

    Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of...

    Research recommendation
    Published
    30 September 2021

  9. Teduglutide for treating short bowel syndrome (TA804)

    Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.

    Technology appraisal guidance
    Published
    30 June 2022
    View recommendations

    Sections for TA804

  10. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  11. Creatinine-based estimate of eGFR – improving accuracy of calculations: In adults, children and young people from black, Asian and other minority ethnic groups with CKD living in the UK, what biomarkers or factors, other than ethnicity, improve the diagnostic accuracy of eGFR calculations?

    and young people from black, Asian and other minority ethnic groups with CKD living in the UK, what biomarkers or factors, other than...

    Research recommendation
    Published
    30 September 2021

  12. Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?

    ID NG203/19 Question Antiplatelet therapy: For people with CKD at the highest risk of cardiovascular disease, what is the clinical...

    Research recommendation
    Published
    30 September 2021

  13. Investigations for proteinuria: What is the effect of measuring proteinuria with albumin:creatinine ratio compared with protein:creatinine ratio on the timing of treatment changes in children and young people with CKD? [2021]

    with CKD? [2021] Any explanatory notes(if applicable) Source guidance details Comes from guidance Chronic kidney disease:...

    Research recommendation
    Published
    30 September 2021

  14. Phosphate binders: Which binders are the most clinically and cost effective in controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis?

    controlling serum phosphate in adults, children and young people with stage 4 or 5 CKD who are not on dialysis? Any explanatory notes(if...

    Research recommendation
    Published
    30 September 2021

  15. Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what is the clinical and cost effectiveness and safety of long-term calcium acetate combined with magnesium carbonate for controlling serum phosphate?

    NG203/17 Question Phosphate binders: In adults with stage 4 or 5 CKD, including those on dialysis, what is the clinical and cost...

    Research recommendation
    Published
    30 September 2021